标题
CAR T-cell immunotherapy of MET-expressing malignant mesothelioma
作者
关键词
-
出版物
OncoImmunology
Volume 6, Issue 12, Pages e1363137
出版商
Informa UK Limited
发表日期
2017-08-14
DOI
10.1080/2162402x.2017.1363137
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells
- (2017) Lynsey M. Whilding et al. MOLECULAR THERAPY
- The role of the HGF/Met axis in mesothelioma
- (2016) Thivyan Thayaparan et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
- (2016) Giuseppe Bronte et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Immunotherapy for malignant mesothelioma: reality check
- (2016) Bibhusal Thapa et al. Expert Review of Anticancer Therapy
- A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial
- (2016) Marissa Mayor et al. Immunotherapy
- Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy
- (2016) Mark O'Hara et al. Immunotherapy
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6
- (2015) Y. Volz et al. BIOSCIENCE REPORTS
- Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
- (2015) A. Hultberg et al. CANCER RESEARCH
- Syndecan-1 alters heparan sulfate composition and signaling pathways in malignant mesothelioma
- (2015) Ghazal Heidari-Hamedani et al. CELLULAR SIGNALLING
- Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release
- (2015) Izabela Komarowska et al. IMMUNITY
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells
- (2015) M. J. Frigault et al. Cancer Immunology Research
- Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors
- (2014) E. K. Moon et al. CLINICAL CANCER RESEARCH
- Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells
- (2014) Leticia Leon et al. CURRENT DRUG TARGETS
- Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor
- (2014) S. Wilkie et al. JOURNAL OF IMMUNOLOGY
- MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
- (2014) Rajani Kanteti et al. PLoS One
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
- (2014) P. S. Adusumilli et al. Science Translational Medicine
- Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?
- (2013) S. J. C. van der Stegen et al. JOURNAL OF IMMUNOLOGY
- Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
- (2013) Petra C Schuberth et al. Journal of Translational Medicine
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
- (2013) G. L. Beatty et al. Cancer Immunology Research
- Heparan Sulfate: A Ubiquitous Glycosaminoglycan with Multiple Roles in Immunity
- (2013) David Anak Simon Davis et al. Frontiers in Immunology
- Immunity and malignant mesothelioma: From mesothelial cell damage to tumor development and immune response-based therapies
- (2012) Valerio Izzi et al. CANCER LETTERS
- The proteoglycan repertoire of lymphoid cells
- (2012) Bodil Fadnes et al. GLYCOCONJUGATE JOURNAL
- Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
- (2012) Scott Wilkie et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group
- (2012) Guénaëlle Levallet et al. Journal of Thoracic Oncology
- Unknown
- (2012) David Davies et al. MOLECULAR MEDICINE
- Cell Membrane–associated Heparan Sulfate Is a Receptor for Prototype Foamy Virus in Human, Monkey, and Rodent Cells
- (2012) Md Nasimuzzaman et al. MOLECULAR THERAPY
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- (2012) Christopher C Kloss et al. NATURE BIOTECHNOLOGY
- The natural history of untreated squamous cell carcinoma of the head and neck: how we do it
- (2011) J.-P. Jeannon et al. CLINICAL OTOLARYNGOLOGY
- Protein Engineered Variants of Hepatocyte Growth Factor/Scatter Factor Promote Proliferation of Primary Human Hepatocytes and in Rodent Liver
- (2011) Jacob Ross et al. GASTROENTEROLOGY
- Heparan Sulfate Modification of the Transmembrane Receptor CD47 Is Necessary for Inhibition of T Cell Receptor Signaling by Thrombospondin-1
- (2011) Sukhbir Kaur et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists
- (2011) Douglas S. Jones et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4
- (2010) Scott Wilkie et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells
- (2009) Koji Kawaguchi et al. CARCINOGENESIS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now